(PRESS RELEASE) SAN RAMON, CA — CooperVision’s global leadership in advancing myopia control and management as standard of care across all ocular health sectors will be in the spotlight at the 2023 European Society of Cataract and Refractive Surgeons (ESCRS) conference. The annual event is expected to draw thousands of ophthalmology clinicians, researchers, and educators to Vienna this week.
The company’s involvement begins on 7 September with a thought leadership panel at the pre-conference Ophthalmology Futures Forum moderated by Marcus Ang, MBBS, PhD, and Ian Flitcroft, DPhil, FRCOphth. Elizabeth Lumb, BSc (Hons) MCOptom, FBCLA, Director of Global Professional Affairs, Myopia Management, CooperVision, will join several industry and clinical colleagues to debate Myopia in the Digital Age, Is Technology the Answer? The discussion is scheduled to begin at 1400 CET at the Hilton Danube Waterfront.
The World Society of Paediatric Ophthalmology and Strabismus’ (WSPOS) Subspecialty Day, sponsored in part by CooperVision, will take place on 8 September. Correction and Control; The Value of Optical Interventions in Myopia Control, will also be led by Lumb. She will engage Ian Flitcroft, whose clinical research pursuits are known worldwide, on his latest explorations regarding evidence-base in respect of low dose atropine and the broader consideration of a clinical management plan in addressing myopia in Western verses Asian populations.
“The global scale of the myopia challenge and the availability of both optical and pharmacological treatments means that this isn’t a question of ophthalmology or optometry, but of cooperation and partnership,” said Flitcroft regarding his vision for the future of myopia management.
“Our engagement with the ophthalmology community through initiatives such as ESCRS underscores CooperVision’s unwavering dedication to advancing ocular health through evidence-based approaches in managing myopia progression.,” said Lumb. “Ophthalmology and the entire eye care professional community play an essential role in fostering innovation, uncovering insights, and contributing to the future of myopia control and management—outcomes we are proud to facilitate and amplify.”
Now prescribed in more than 30 countries, CooperVision’s MiSight 1 day is clinically proven and indicated to slow the progression of myopia in children.1 The company also offers a range of orthokeratology contact lens designs and a spectacle lens with with Diffusion Optics Technology for myopia management. For more information on the Opthalmology Futures Forum, including free registration to view the panels online, visit here.
Advertisement
